Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.

Investment Management

Lilly Asia Ventures

Managing Directors

Jieyu Zou

Stella Shi

Qinwei Zhou

Min Li

Sean Zhang

Ting Feng

Yu Cao

Yaping Shou

Li Xu

Tao Yu

Lilian Wan

Ling Su

Judith Li

Bin Li

Cong Xu

Hansen Xu

Gavin Xia

Zhihui Wang

Xiaodi Su

Joe Shih

Yi Shi

Fei Chen

Andiely Lu

Liang Lin

Josh Jin

Darren Ji

Yun Gao

Lilly Asia Ventures' Leadership Team includes Liang Lin and 26 others.

Leadership Team

Leadership Team

About

Team members